Thus far, the risk of worsening diabetic retinopathy by DPSC‐CM administration to the lower limb does not seem high, because a clinical trial for diabetic polyneuropathy showed that VEGF gene transfer to the legs did not show worse proliferative retinopathy27. The gene discussed is VEGFA; the disease is diabetic neuropathy.